Anti-Inflammatory Effects of MiR-369-3p Via PDE4B in Intestinal Inflammatory Response

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Aug 10

PMID 39126032

Authors

Viviana Scalavino

Emanuele Piccinno

Nicoletta Labarile

Raffaele Armentano

Gianluigi Giannelli

Grazia Serino

Affiliations

Soon will be listed here.

Abstract

Cyclic nucleotide phosphodiesterases (PDEs) consist of a family of enzymes expressed in several types of cells, including inflammatory cells, that play a pivotal role in inflammation. Several studies have demonstrated that the inhibition of PDE4 results in a reduced inflammatory response via PKA and CREB signaling. Hence, PDE4 suppression improves the inflammatory feedback typical of several diseases, such as inflammatory bowel disease (IBD). In our previous studies, we have demonstrated that miR-369-3p regulates inflammatory responses, modulating different aspects of the inflammatory process. The aim of this study was to demonstrate an additional anti-inflammatory effect of miR-369-3p targeting PDE4B, one of the widely expressed isoforms in immune cells. We found that miR-369-3p was able to reduce the expression of PDE4B, elevating the intracellular levels of cAMP. This accumulation increased the expression of PKA and pCREB, mitigating the release of pro-inflammatory cytokines and promoting the release of anti-inflammatory cytokines. To prove that PDE4B is a good therapeutic target in IBD, we also demonstrate that the expression of PDE4B was increased in UC patients compared to healthy controls, affecting the immune infiltrate. PDE4B is considered an important player in inflammatory progression; hence, our results show the ability of miR-369-3p to ameliorate inflammation by targeting PDE4B, supporting its future application as a new therapeutic approach in IBD.

References

Loher F, Schmall K, Freytag P, Landauer N, Hallwachs R, Bauer C . The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther. 2003; 305(2):549-56. DOI: 10.1124/jpet.102.039529. View

Scalavino V, Liso M, Serino G . Role of microRNAs in the Regulation of Dendritic Cell Generation and Function. Int J Mol Sci. 2020; 21(4). PMC: 7072926. DOI: 10.3390/ijms21041319. View

Kawamatawong T . Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis. 2017; 9(4):1144-1154. PMC: 5418297. DOI: 10.21037/jtd.2017.03.116. View

Galleggiante V, De Santis S, Liso M, Verna G, Sommella E, Mastronardi M . Quercetin-Induced miR-369-3p Suppresses Chronic Inflammatory Response Targeting C/EBP-β. Mol Nutr Food Res. 2019; 63(19):e1801390. DOI: 10.1002/mnfr.201801390. View

Tavares L, Negreiros-Lima G, Lima K, E Silva P, Pinho V, Teixeira M . Blame the signaling: Role of cAMP for the resolution of inflammation. Pharmacol Res. 2020; 159:105030. DOI: 10.1016/j.phrs.2020.105030. View

Raisch J, Darfeuille-Michaud A, Nguyen H . Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol. 2013; 19(20):2985-96. PMC: 3662938. DOI: 10.3748/wjg.v19.i20.2985. View

Huang B, Chen Z, Geng L, Wang J, Liang H, Cao Y . Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways. Cell. 2019; 179(5):1160-1176.e24. DOI: 10.1016/j.cell.2019.10.027. View

Spadaccini M, DAlessio S, Peyrin-Biroulet L, Danese S . PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017; 18(6). PMC: 5486098. DOI: 10.3390/ijms18061276. View

Chen Y, Wang X . miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2019; 48(D1):D127-D131. PMC: 6943051. DOI: 10.1093/nar/gkz757. View

10.

Francis S, Blount M, Corbin J . Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev. 2011; 91(2):651-90. DOI: 10.1152/physrev.00030.2010. View

11.

Milakovic M, Gooderham M . Phosphodiesterase-4 Inhibition in Psoriasis. Psoriasis (Auckl). 2021; 11:21-29. PMC: 7982714. DOI: 10.2147/PTT.S303634. View

12.

Yang J, Hsieh K, Chen Y, Lee C, Conti M, Chuang T . Phosphodiesterase 4B negatively regulates endotoxin-activated interleukin-1 receptor antagonist responses in macrophages. Sci Rep. 2017; 7:46165. PMC: 5382768. DOI: 10.1038/srep46165. View

13.

Piccinno E, Scalavino V, Armentano R, Giannelli G, Serino G . miR-195-5p as Regulator of γ-Catenin and Desmosome Junctions in Colorectal Cancer. Int J Mol Sci. 2023; 24(23). PMC: 10707010. DOI: 10.3390/ijms242317084. View

14.

Manning C, Burman M, Christensen S, Cieslinski L, Essayan D, Grous M . Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999; 128(7):1393-8. PMC: 1571768. DOI: 10.1038/sj.bjp.0702911. View

15.

Scalavino V, Piccinno E, Valentini A, Mastronardi M, Armentano R, Giannelli G . A Novel Mechanism of Immunoproteasome Regulation via miR-369-3p in Intestinal Inflammatory Response. Int J Mol Sci. 2022; 23(22). PMC: 9691197. DOI: 10.3390/ijms232213771. View

16.

Scalavino V, Piccinno E, Lacalamita A, Tafaro A, Armentano R, Giannelli G . miR-195-5p Regulates Tight Junctions Expression via Claudin-2 Downregulation in Ulcerative Colitis. Biomedicines. 2022; 10(4). PMC: 9029592. DOI: 10.3390/biomedicines10040919. View

17.

Schmidt L, Wang C, Patel V, Davidson D, Kalirai S, Panda A . Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors. Dermatol Ther (Heidelb). 2023; 13(9):2019-2030. PMC: 10442291. DOI: 10.1007/s13555-023-00975-3. View

18.

Perez-Aso M, Carmen Montesinos M, Mediero A, Wilder T, Schafer P, Cronstein B . Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015; 17:249. PMC: 4570588. DOI: 10.1186/s13075-015-0771-6. View

19.

Dhuppar S, Murugaiyan G . miRNA effects on gut homeostasis: therapeutic implications for inflammatory bowel disease. Trends Immunol. 2022; 43(11):917-931. PMC: 9617792. DOI: 10.1016/j.it.2022.09.003. View

20.

Jung H, Kim J, Lee K, Tizaoui K, Terrazzino S, Cargnin S . Roles of microRNAs in inflammatory bowel disease. Int J Biol Sci. 2021; 17(8):2112-2123. PMC: 8193269. DOI: 10.7150/ijbs.59904. View